)
Visual
test
Spago Nanomedical
Spago Nanomedical (SPAGO) investor relations material
Spago Nanomedical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Feb, 2026
Executive summary
Achieved key clinical milestones in the Tumorad program, including DMC recommendation for dose escalation and proof-of-concept in humans for 177Lu-SN201, supporting further development and potential orphan drug designation.
Completed an oversubscribed rights issue, raising approximately SEK 25 million before costs, strengthening financial position for continued clinical development.
Focused on advancing Tumorad to Phase II and exploring strategic partnerships for SpagoPix, with ongoing business development for out-licensing or collaboration.
Financial highlights
Net sales for the year were KSEK 437, down from KSEK 1,911 year-over-year; quarterly net sales were KSEK 4, down from KSEK 617.
Full-year loss amounted to KSEK -26,554, an improvement from KSEK -32,509 the previous year; quarterly loss was KSEK -5,890, improved from KSEK -7,830.
Operating expenses for the year decreased to KSEK -31,766 from KSEK -40,626, mainly due to headcount reductions and focus on clinical activities.
Cash and cash equivalents at year-end were KSEK 29,672, compared to KSEK 32,470 last year.
Earnings per share for the year were SEK -0.07 (SEK -0.11), and for the quarter SEK -0.01 (SEK -0.02).
Outlook and guidance
Tumorad Phase I/IIa study progressing as planned, with next DMC review scheduled for March to assess maximum tolerated dose.
Focus on securing long-term financing and maintaining flexibility for Phase II development and potential strategic collaborations.
Continued business development for SpagoPix, with further clinical development dependent on partnerships or external funding.
ODD for ACC: Impact on Tumorad development
SpagoPix partnering timeline and strategy
How will Tumorad Phase II be financed?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Spago Nanomedical earnings date
Q1 20266 May, 2026
Spago Nanomedical
Next Spago Nanomedical earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Spago Nanomedical AB is a Swedish biotechnology company that specializes in nanomedicine for cancer diagnostics and treatment. The company is advancing two main projects: SpagoPix and Tumorad. SpagoPix is an MRI contrast agent under clinical development, aimed at improving cancer diagnostics by selectively enhancing tumor visibility in breast, liver, and pancreatic cancers. Tumorad is a radionuclide therapy that targets cancer cells using nanoparticles, currently in preclinical stages for treating advanced cancers. Spago Nanomedical is based in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage